Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA II Tumor Marker)

In the absence of vitamin K, liver cells cannot depend on vitamin K in the synthesis of standard clotting factors, only the synthesis of no function of blood coagulation abnormal prothrombin (DCP) -- pivka 2 tumor marker , is the protein induced by vitamin K deficiency or antagonist - II, can appear in vitamin K deficiency or the serum of patients with hepatocellular carcinoma (HCC).

At present, Chinese and foreign guidelines have listed PIVKA II antibody as a significant indicator for liver cancer detection. 
Pivka-ii has been written into the guidelines by the Asian-Pacific Society of Hepatology and the Japanese Society of Hepatology and recommended high-risk screening populations as an auxiliary diagnosis of liver cancer, monitoring treatment effect, and prognostic and recurrence prediction tool.
PIVKA II Intro
Pivka ii antibody is a vitamin K deficiency or antagonist-II-induced protein, also known as abnormal prothrombin (Des-gamma-carboxy prothrombin, DCP). Normal liver in vitamin K Prothrombin is produced under the action. Still, abnormal prothrombin is made in patients with vitamin K deficiency or hepatocellular carcinoma. Its serum level is in patients with vitamin K deficiency, patients treated with warfarin, or patients with hepatocellular carcinoma (HCC). It will be elevated in serum and can be used to diagnose HCC.
PIVKA II Test
PIVKA 2 is used to diagnose hepatocellular carcinoma, which is helpful for the screening of high-risk groups. It is helpful for the auxiliary diagnosis of hepatocellular carcinoma when combined with imaging such as ultrasound detection. The serum half-life of PIVKA-II is about 40 to 72 hours, which is shorter than that of AFP. 3 to 5 days can more timely reflect the efficacy of HCC.

As a professional tumor marker factory, SEKBIO has high-quality tumor marker for sale. Welcome to contact us if needed.